الفهرس 
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 142 |  |  |
| | | from | 142 | | |
Abstract
SUMMERY
Human papillomavirus causes the vast majority of skin warts (HPV). Social shame, discomfort, and irritation are common reasons people seek treatment for warts despite the fact that most warts are asymptomatic and over half of cutaneous warts disappear within 1-2 years.
Topical salicylic acid and cryotherapy (separately or in combination) are the usual destructive methods of choice for the first treatment of cutaneous warts. Imicumod, dinitrochlorobenzene, 5-fluorouracil, immunotherapy, duct tape, photo- dynamic therapy, pulsed dye laser, and surgical removal are only some of the additional treatment methods that have been researched for the usage in recalcitrant warts.
Traditional invasive procedures may cause discomfort, infection, scarring, dyspigmentation, and even a 30% chance of recurrence. It is believed that dormant virus reappears near the initial wart, which causes recurrence.
Intralesional immunotherapy makes use of the immune system’s recognition of specific viral, bacterial, and fungal antigens, like Candida or Trichophyton antigens, to induce a delayed-type hypersensitivity reaction, not only to the antigen but also against the wart virus. This boosts the immune system’s ability to recognize and eradicate HPV. After being triggered, the immune system may eliminate not only the locally treated lesion, but all lesions on the body.
The purpose of this meta-analysis research was to examine the indications, contraindications, varying outcomes, and potential hazards of candida antigen immunotherapy for the treatment of warts.
PubMed, EMBASE, and the Cochrane Database of Systematic Reviews will be used to search for peer-reviewed medical literature in English. In the end, 27 papers were accepted for the analysis.
The overall percentage of full remission of wart lesions was 66.7% (927/1389) while the overall rate of partial remission was 20.4%. (out of 657 cases 134 cases had PR). Candida antigen treatment resulted in a low percentage of relapse (2.3 percent recurrence rate).
Patients given candida antigen in this trial had a much higher incidence of full remission than those given placebo, but there was no significant difference between the two groups in terms of the rate of partial remission. When compared to the placebo group, those receiving Candida antigen showed a statistically substantially reduced incidence of no response. This meta-analysis found no significant difference in full remission rates between candida antigen and vitamin D, although individual trials exhibited mixed findings. The percentage of nonresponders to candida antigen and vitamin D treatment was similar. When comparing the incidence of partial remission, Candida antigen performed somewhat better than vitamin D.
Complete remission rates for cases treated with candida antigen were found to be greater than those for those treated with PPD, according to the trials included in this paper. We discovered no statistically significant difference in partial remission rates between the candida antigen group and the PPD group. There were significantly less patients that did not react to therapy when using Candida antigen compared to when using PPD.
Results showed a much greater incidence of full remission in the Candida Antigen group compared to the MMR group. We discovered that the rate of partial remission in the MMR group was not significantly different from that in the candida antigen group. Compared to the MMR group, the rate of patients with no response was much lower in the Candida Antigen group.
Last but not least Compared to placebo, PPD, and MMR, and with no significant difference to vitamin D, our findings reveal that intralesional Candida antigen treatment for cutaneous warts is an effective alternative in a clinical practice scenario, with a full remission rate of wart lesion of 66.7%. The incidence of partial remission for those treated with Candida was not significantly different from those treated with placebo, vitamin D, PPD, or MMR.